AstraZeneca
Immunomedics’ whirlwind in the C-suite continues
April 10, 2018Manufacturing and Production, Medical Communications AstraZeneca, Immunomedics, Seattle Genetics, biotech, drugs, pharma, pharmaceutical
Immunomedics hasn’t had the most straight forward year, its $2 billion deal with Seattle Genetics was scuppered by activist investors, …
AZ’s MedImmune signs $200m immuno-oncology partnership with Compugen
April 3, 2018Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Cancer, MedImmune, compugen, immunotherapy, oncology, pharma
AstraZeneca’s biologic R&D unit MedImmune is set to enter a partnership with Israeli drug firm Compugen to develop bi-specific and …
Top Ten most popular articles on Pharmafile.com this week
March 16, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Andrew Witty, AstraZeneca, BMS, Biocon, Martin Shkreli, Novartis, Right to try, US, pharma, top ten
Another week goes by, and we may have finally reached Spring here in the UK. Friday means its time for …
Adaxis-AZ immunotherapy combo hit by clinical hold after death
March 13, 2018Manufacturing and Production, Research and Development Adaxis, AstraZeneca, Imfinzi, biotech, drugs, immunotherapy, pharma, pharmaceutical
Adaxis and AstraZeneca announced that they had agreed a combination program for axalimogene filolisbac and Imfinzi, respectively, back in 2014 …
AstraZeneca’s Brilinta proves safety in heart attack patients at Phase 3
March 12, 2018Research and Development, Sales and Marketing AstraZeneca, Brilinta, heart attack
AstraZeneca has revealed new Phase 3 data on its direct-acting P2Y12 receptor antagonist Brilinta (ticagrelor) at the American College of …
Uncovering trends in the future of real world data
March 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, AstraZeneca, feature, pharma, real world data, real world evidence
A new report has canvassed the intentions of industry players in the use of real world data and evidence over …
Top Ten most popular articles on Pharmafile.com this week
March 2, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Alzheimer's, AstraZeneca, Botox, Celgene, EMA, FDA, Merck, Mylan, Pfizer, Roche, Takeda, ipsen, vaccines
We’re already into March and, trying to put a bad start to the year behind them on Alzheimer’s research, the …
AstraZeneca creates biotech spin-off, $250m in bank
February 28, 2018Research and Development, Sales and Marketing AstraZeneca, Viela, biotech, drugs, pharma, pharmaceutical
Biotechs created from big pharma companies tend to have an easier start to life than most, and this is definitely …
Top Ten most popular articles on Pharmafile.com this week
February 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Alzheimer's, AstraZeneca, Eylea, FDA, Microsoft, Regeneron, Shire, Tremfya, eurordis, multiple myeloma, rare disease
It’s the last Friday of February, and it’s time for another run-down of the most popular stories of the week. …
CDC U-turns previous decision on AZ’s flu vaccine
February 22, 2018Sales and Marketing AstraZeneca, Vaccine, biotech, drugs, flu, influenza, pharma, pharmaceutical
The US Centers for Disease Control and Prevention (CDC) has now recommended AstraZeneca’s FluMist as an option for doctors for …
AZ licenses kidney drug from Ionis for $330m
February 21, 2018Research and Development, Sales and Marketing AstraZeneca, Ionis, Isis, biotech, drugs, kidney, pharma, pharmaceutical
AstraZeneca continues to build on its relationship with San Diego-based Ionis Pharmaceuticals, this time by agreeing a licensing deal for …
AZ’s Imfinzi seals blockbuster lung cancer market with FDA nod
February 19, 2018Sales and Marketing AstraZeneca, Imfinzi, biotech, drugs, pharma, pharmaceutical
AstraZeneca’s immunotherapy, Imfinzi, arrived to the industry as a failure – there were big hopes resting on the company’s Mystic …
Top Ten most popular articles on Pharmafile.com this week
February 2, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ablynx, Alzheimer's, Apotex, AstraZeneca, Brexit Health Alliance, CDC, Duchenne Muscular Dystrophy, EMA, Italy, Sanofi, amazon, brexit, santhera, top ten
It’s the first Friday of February, and it’s time for another recap of the top ten articles most popular with …
Faslodex rejected by NICE for NHS breast cancer use
February 2, 2018Research and Development, Sales and Marketing AstraZeneca, Faslodex, NHS, NICE, UK, pharma
Bad news for breast cancer patients in the UK as the National Institute for Health and Care Excellence announces it …
Array BioPharma demands $192m after AstraZeneca refuses to pay royalties
February 2, 2018Medical Communications, Sales and Marketing Array Biopharma, AstraZeneca, lawsuit, selemetinib
Array BioPharma has launched a lawsuit against AstraZeneca over allegations the latter has refused to pay royalties it owes for …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
